Qarziba (dinutuximab beta)

The patient was treated with systemic conventional and high-dose chemotherapy combined with intrathecal Topotecan. This case suggests that anti-GD2 immunotherapy, used as consolidation treatment, may improve the prognosis of patients with advanced retinoblastoma and potentially reduce the toxicity associated with standard therapies. Further clinical investigation is warranted to validate these findings.

P2, N=41, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Sep 2027

P1, N=44, Active, not recruiting, University Hospital Southampton NHS Foundation Trust | Trial completion date: Jul 2025 --> Nov 2025

Several proteins not previously associated, or only indirectly linked, with beta cell function, apoptosis, or proliferation were identified and characterized for the first time in insulinoma. These findings provide new insights and potential targets for the treatment of pancreatic cancer.

P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026

P3, N=750, Recruiting, Children's Oncology Group | Trial completion date: Sep 2026 --> Sep 2030 | Trial primary completion date: Sep 2026 --> Sep 2030

Chemo-immunotherapy can benefit HR-NBL patients with PD before HDC, including those with progression during/at the end of the induction chemotherapy and NMYC amplification. These findings support its early inclusion in HR-NBL trials.

P3, N=750, Recruiting, Children's Oncology Group | Active, not recruiting --> Recruiting

Sensitivity analyses and unadjusted comparisons supported the results. In the indirect comparison, dinutuximab beta significantly extended PFS and increased ORR compared to naxitamab.

Dinutuximab beta LTI was well tolerated and clinically active in patients with relapsed/refractory high-risk neuroblastoma, with Fc-gamma receptor polymorphisms and natural killer cells identified as prognostic biomarkers.

P1, N=38, Recruiting, Princess Maxima Center for Pediatric Oncology | Not yet recruiting --> Recruiting

Dinutuximab beta also triggers autophagy in NB cells, and inhibition of the VEGFR pathway with anlotinib amplifies dinutuximab beta-induced autophagy. Furthermore, autophagy inhibition by CQ enhances CXCL9 expression and anti-tumor T cell responses of single anti-GD2 therapy in vitro and in vivo. Collectively, this study suggests autophagy inhibitors may be a promising strategy for enhancing therapeutic efficacy in NB in conjunction with anti-GD2 immunotherapy.